What Can Go Wrong in the Non-coding Genome and How to Interpret Whole Genome Sequencing Data
Overview
Medical Ethics
Affiliations
Whole exome sequencing discovers causative mutations in less than 50 % of rare disease patients, suggesting the presence of additional mutations in the non-coding genome. So far, non-coding mutations have been identified in less than 0.2 % of individuals with genetic diseases listed in the ClinVar database and exhibit highly diverse molecular mechanisms. In contrast to our capability to sequence the whole genome, our ability to discover and functionally confirm such non-coding mutations is lagging behind severely. We discuss the problems and present examples of confirmed mutations in deep intronic sequences, non-coding triplet repeats, enhancers, and larger structural variants and highlight their proposed disease mechanisms. Finally, we discuss the type of data that would be required to establish non-coding mutation detection in routine diagnostics.
An estimation of global genetic prevalence of PLA2G6-associated neurodegeneration.
Kurtovic-Kozaric A, Singer-Berk M, Wood J, Evangelista E, Panwala L, Hope A Orphanet J Rare Dis. 2024; 19(1):388.
PMID: 39425167 PMC: 11489993. DOI: 10.1186/s13023-024-03275-x.
Nomakuchi T, Teferedegn E, Li D, Muirhead K, Dubbs H, Leonard J Am J Med Genet A. 2024; 194(12):e63817.
PMID: 39031459 PMC: 11540733. DOI: 10.1002/ajmg.a.63817.
Brlek P, Bulic L, Bracic M, Projic P, Skaro V, Shah N Cells. 2024; 13(6.
PMID: 38534348 PMC: 10969765. DOI: 10.3390/cells13060504.
Systematic assays and resources for the functional annotation of non-coding variants.
Kircher M, Ludwig K Med Genet. 2023; 34(4):275-286.
PMID: 37034418 PMC: 10081529. DOI: 10.1515/medgen-2022-2161.
POSTRE: a tool to predict the pathological effects of human structural variants.
Sanchez-Gaya V, Rada-Iglesias A Nucleic Acids Res. 2023; 51(9):e54.
PMID: 36999617 PMC: 10201441. DOI: 10.1093/nar/gkad225.